Compositions and methods for treating renal injury
Inventors
Markowitz, Sanford • Kim, Sun-Hee • Kim, Hye Jung • Bae, Ki Beom
Assignees
Inje Industry Academic Cooperation Foundation • Case Western Reserve University
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A method for preventing or treating renal disorder, disease, and/or injury includes administering to the subject and/or kidney a therapeutically effective amount of a 15-PGDH inhibitor.
Core Innovation
The invention relates to preventing or treating contrast agent induced acute kidney injury (CIAKI) in a subject in need thereof by administering a therapeutically effective amount of a 15-PGDH inhibitor. The 15-PGDH inhibitor is used to induce endogenous renal PGE2 and to improve renal hemodynamics, with documented renal vasodilation, preservation of renal blood flow, and resistance to hypoxia.
The disclosure reports reductions in oxidative stress, inflammation, and renal injury markers, including creatinine, NGAL, KIM-1, BUN, MDA, HMGB1, tubular necrosis, and apoptosis. It also describes reversal of decreases in renal AMP and adenosine, altered prostaglandin E2 receptor expression including increased EP4 and decreased EP3, and an EP4 receptor/cAMP/AMP/adenosine pathway.
The disclosure further recites broad structural variability for 15-PGDH inhibitors, including compounds of formula (V) and pharmaceutically acceptable salts, tautomers, or solvates, with defined structural parameters. The contrast agent context is focused on iodinated radiographic contrast agents and specified iodinated contrast compounds, and the methods include administration before contrast agent administration.
Claims Coverage
The independent claim coverage centers on administering a therapeutically effective amount of a 15-PGDH inhibitor to prevent or treat contrast agent induced acute kidney injury (CIAKI). The claims further refine the inhibitor by defined chemical formula parameters and pharmaceutically acceptable forms, refine the contrast agent to iodinated radiographic agents and named iodinated compounds, and include biological outcome targets and a pre-contrast timing window.
Therapeutically effective 15-PGDH inhibitor administration for CIAKI prevention or treatment
A method for preventing or treating contrast agent induced acute kidney injury (CIAKI) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
Defined 15-PGDH inhibitor structural formula and allowed variants
The method further specifies that the 15-PGDH inhibitor is a compound having formula (V), including pharmaceutically acceptable salt, tautomer, or solvate, with defined structural parameters.
Use of an iodinated radiographic contrast agent
The method includes administering or using a contrast agent that is an iodinated radiographic contrast agent.
Use of a contrast agent selected from specified iodinated compounds
The method includes a contrast agent made from at least one specified iodinated contrast compound selected from the listed options including acetrizoate, diatrizoate, iodamide, ioglicate, iothalamate, ioxithalamate, metrizoate, metrizamide, iohexol, iopamidol, iopentol, iopromide, and ioversol.
Biological outcome targets associated with reduced kidney injury and inflammation
The method administers an effective amount of a 15-PGDH inhibitor to lower MDA and NGAL, lessen medullary tubular injury including ATN and apoptosis, reduce HMGB1 and proinflammatory cytokines, upregulate renal EP4 PGE2 and A2A adenosine receptors, increase renal cAMP, AMP, and adenosine levels, and inhibit induction of creatinine and KIM-1.
Pre-administration timing window before contrast agent dosing
A 15-PGDH inhibitor is administered between about 1 minute and about 72 hours before contrast agent administration.
The claim set covers preventing or treating CIAKI by administering a therapeutically effective amount of a 15-PGDH inhibitor, with dependent coverage refining the inhibitor by a defined structural formula and allowable forms, restricting the contrast agent to iodinated radiographic agents and specific named iodinated contrast compounds, associating treatment with specific biological outcome targets, and including a defined pre-contrast timing window.
Stated Advantages
Induces endogenous renal PGE2.
Provides renal vasodilation and preserves renal blood flow.
Improves renal hemodynamics.
Provides resistance to hypoxia.
Reduces oxidative stress and inflammation.
Reduces renal injury markers including creatinine, NGAL, KIM-1, BUN, and MDA.
Reduces tubular necrosis and apoptosis.
Restores renal AMP and adenosine and increases EP4 signaling.
EP4 antagonism attenuates the renoprotective effects.
Protects cultured human renal proximal tubular epithelial cells from iodixanol-induced apoptosis.
Improving hERG activity while maintaining PDGH activity.
Documented Applications
Prevention or treatment of contrast agent induced acute kidney injury (CIAKI) in a subject in need thereof.
Protection against iodixanol (Visipaque)-induced CIAKI, including reductions in creatinine, NGAL, KIM-1, and attenuation of outer-medulla necrosis and apoptosis.
Protection of cultured human renal proximal tubular epithelial cells from iodixanol-induced apoptosis.
Use of 15-PGDH inhibition in ischemic AKI models involving renal IRI, with reduced renal injury markers, tubular necrosis, apoptosis, and inflammatory induction.
Preventing or treating CIAKI in a subject using administration of a 15-PGDH inhibitor in the presence of iodinated radiographic contrast agents.
The document also describes medicinal-chemistry performance considerations of 15-PGDH inhibitors, including improving hERG activity while maintaining PDGH activity.
Interested in licensing this patent?